Kevin W. Chamberlin, PharmD
Kevin W. Chamberlin, PharmD, is associate clinical professor and assistant department head, pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.
FDA approves sacubitril/valsartan to treat heart failure
For patients with heart failure, Entresto is the first treatment available that has been shown to decrease hospitalizations and reduce the risk of cardiovascular-related death.
FDA approves eluxadoline to treat IBS-D in adults
Few treatment options are available for irritable bowel syndrome with diarrhea. Eluxadoline acts on the nervous system to lessen bowel contraction.
FDA approves ceftazidime-avibactam to treat two complicated infections
The combination product is indicated to treat either complicated intra-abdominal infections, where it is used in combination with metronidazole, or complicated urinary tract infections in patients with few or no other treatment options.
FDA approves ferric citrate to treat hyperphosphatemia in dialysis patients
Auryxia, an iron-based phosphate binder, was approved September 5, 2014.
FDA approves extended-release oxycodone combo to deter abuse
An opioid analgesic with an abuse deterrent,Targiniq can deter but not entirely prevent abuse when snorted or injected.
FDA approves droxidopa to treat neurogenic orthostatic hypotension
NOH is a rare, chronic, and debilitating drop in blood pressure upon standing. It is associated with Parkinson's disease, multiple system atrophy, and pure autonomic failure.
Breo Ellipta: A new fixed-dose inhalation combo for COPD patients
FDA approves a powder delivery system combining a corticosteroid and a LABA.
New SSRI approved in last quarter of 2013
FDA approved vortioxetine as oral tablets indicated for the treatment of major depressive disorder.
FDA approves 4PCC for acute major bleeding
CSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.
FDA approves third oral agent for MS
Dimethyl fumarate (Tecfidera, Biogen Idec) oral delayed-release capsules, formerly called BG-12, was approved by the FDA on March 27, 2013 for the treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be recently approved for the treatment of these types of MS.
  • 1
  • 2


View Results